BAMBI promotes macrophage proliferation and differentiation in gliomas

DAN WANG1, XIAOLAI CHEN1 and RAN ZHANG2

1Department of Neurosurgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005; 2Department of Immunology, Hunan Normal University School of Medicine, Changsha, Hunan 410031, P.R. China

Received November 30, 2015; Accepted November 15, 2016
DOI: 10.3892/mmr.2017.8320

Abstract. The present study investigated the capacity of Bone morphogenic protein and activin membrane-bound inhibitor homolog (BAMBI) to regulate the migration and differentiation of macrophages in gliomas. Using a migration assay, it was determined that BAMBI stimulated monocytes migration in a dose-dependent effect. When induced by phorbol myristate acetate (PMA) the monocytes differentiated into macrophages, and BAMBI also increased the migration of PMA-induced macrophages compared with control cells. The expression of CD68 and BAMBI protein and mRNA in glioma and normal specimens were detected using immunohistochemistry and reverse transcription-quantitative polymerase chain reaction, respectively. The localization of BAMBI was primarily in macrophages, as demonstrated by staining for the macrophage marker CD68, and the mRNA expression of CD68 and BAMBI were higher in gliomas compared to normal tissues. In addition, the mRNA expression of CD68 and BAMBI were positively correlated (R²=0.64). After treatment with 50 nM PMA and 10 nM BAMBI for 48 h, RAW 264.7 macrophages were exhibited dendrite-like morphology, indicating that the co-treatment promoted the differentiation of monocytes to macrophages. The expression of specific markers of M1 [inducible nitric oxide synthase (iNOS) and interleukin (IL)-12] and M2 (IL-10 and arginase 1) type macrophages was determined following 10 nM BAMBI treatment. BAMBI promoted the expression of M1 markers, whereas the M2 markers were not affected, which indicated that BAMBI induced differentiation of M1 type macrophages. These results indicate that BAMBI may be involved in macrophage differentiation in gliomas.

Introduction

Inflammation has been previously defined to have important role in various pathologies, including gliomas (1-3). Currently, there is no clear cause of glioma development. The probable causative factors may involve infectious agents, dietary factors or estrogens (3). Within the various inflammatory cell populations of the nervous system, it has been recognized that macrophages are one of the important inflammatory components. However, there are conflicting results regarding the contributory mechanisms of macrophages in the inflammatory process.

Previous studies demonstrated that chronic inflammation may be associated with high-grade gliomas and then result in a high risk of glioma development (4,5). Increased numbers of macrophages have been detected in chronic inflammatory infiltrates of gliomas (1,6). They have also been associated with tissue injuries. Compared with normal tissues and cells, numerous inflammatory cytokines are overexpressed in gliomas (1,7,8). However, how immune infiltrates are involved in the progression and prognosis of gliomas remains unclear. A high level of tumor-associated macrophages (TAMs) is an independent predictor for disease-free survival for ovarian cancer (9). Additionally, a polarized M2 phenotype is produced by tumor-derived and T cell-derived cytokines in macrophages which may be associated with cancer progression (9). Decreased number of macrophages reduced angiogenesis and tumor growth, and macrophages regulate hormonal resistance in gliomas (10).

Bone morphogenic protein (BMP) and activin membrane-bound inhibitor homolog (BAMBI) is a transmembrane glycoprotein which shares certain homology with type I receptors of the transforming growth factor-β (TGF-β) family (11). The extracellular domain of BAMBI is homologous to the protein sequence of T-box brain protein 1 (TBR1). Thus, BAMBI is a pseudoreceptor of TBR1. BAMBI is widely-expressed, including in nervous system and ovarian cancer (11,12). BAMBI is also overexpressed in different types of cancer (11,13). Upregulation of BAMBI is correlated with tumor growth and metastasis via escape from growth arrest by TGFβ (14). Furthermore, BAMBI has been demonstrated to be that co-expressed with BMP, TGF-β and activin, which indicates a potential function of BAMBI in mediating...
macrophage proliferation (15). In addition, the expression of BAMBI is regulated by lysosomal/autolysosomal degradation indicating that there is an association between BAMBI and immune activities in renal endothelial cells (16). In addition, these effects of BAMBI may be crucial in cancer progression via stimulating macrophage proliferation (16). However, the link between immunomodulatory activity of BAMBI and inflammation-associated glioma development requires further investigation.

It has been previously demonstrated that macrophages have an important role in cancer (17). BAMBI has been demonstrated to be highly expressed in macrophages (18). However, few studies have investigated the direct effect of BAMBI on monocyte/macrophage migration and differentiation, or the association between BAMBI expression levels and macrophage density in human glioma in specimens. In the present study, the effect of BAMBI on monocytes and macrophages was evaluated via cell migration assay, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting, and immunohistochemistry using gliomas tissues. The results demonstrated that BAMBI increased monocyte migration and activated macrophages in vitro, and that the BAMBI expression levels were positively associated with macrophage density in human glioma.

Materials and methods

Patients. Formalin-fixed, paraffin-embedded adjacent normal tissue (n=27) and glioma (n=27; Gleason score, 6-7) specimens were obtained from Hunan Provincial People's Hospital of Hunan Normal University (Changsha, China). The characteristics of the patients are presented in Table I. The specimens were diagnosed and scored by specialized pathologists via hematoxylin and eosin staining (Beyotime Institute of Biotechnology, Beijing, China). Written informed consent was obtained from each patient and the study was approved by the Ethics Committees of Hunan Provincial People's Hospital of Hunan Normal University.

Cell lines. RAW 264.7 macrophages were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and the cells were cultivated in Dulbecco's modified Eagle's medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.). THP-1 monocytes (ATCC) were cultured in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) with 10% FBS. Differentiation of monocytes into macrophages was induced using 50 nM phorbol myristate acetate (PMA; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) for 48 h (11). The U-87 glioma cell line (ATCC) was cultivated in RPMI-1640 medium with 10% FBS. All the cells were cultured at 37˚C with 5% CO2.

Cell migration assay. The cell migration was assayed using 48-well Boyden chambers (Neuro Probe, Inc., Gaithersburg, MD, USA). Monocytes (2x105 cell/ml) were seeded on the top of the chamber membrane. RPMI-1640 containing 10% FBS (Gibco-BRL, Grand Island, NY, USA) and 1 or 10 nM BAMBI (Sino Biological, Inc., Beijing, China) was added to the bottom of the well. RPMI-1640 without FBS was added to the top chamber. Control wells received no treatment. After incubation for 10 h, the migrated cells were stained using Crystal Violet Staining Solution for 15 min at 37˚C (Sangon Biotech Co., Ltd., Shanghai, China). The migrated cells were imaged using a Leica 400 light microscope (Leica Microsystems, Inc., Buffalo Grove, IL, USA) and the number of cells in 10 fields was calculated by Image-Pro Plus software, version 5.0 (Media Cybernetics, Inc., Rockville, MD, USA).

Table I. Clinicopathological characteristics of the patients within the study.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>13</td>
</tr>
<tr>
<td>Female</td>
<td>14</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>20-45</td>
<td>16</td>
</tr>
<tr>
<td>46-60</td>
<td>11</td>
</tr>
<tr>
<td>Glioma histopathology grade</td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>13</td>
</tr>
<tr>
<td>III-IV</td>
<td>14</td>
</tr>
</tbody>
</table>

RT-qPCR. RNA was extracted from cells or tissues using RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA). Total RNA (1 µg) was reverse transcribed to cDNA using the Verso cDNA Synthesis kit (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. The qPCR reaction was performed on an ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using Premix Ex Taq™ PCR kit (Perfect Real-Time; Takara Biotechnology Co., Ltd., Dalian, China) with the following conditions: Initial denaturating for 30 sec at 95˚C; then 40 cycles of 30 sec at 95˚C and 30 sec at 60˚C. The primers used were as follows: BAMBI forward, 5'-CTCAAAATCCCCACTCACCA-3' and reverse, 5'-GCTGATACCTGTTCCTGTCGTG-3'; CD68 forward, 5'-GCC TGG AGC CTC AGG GAG A-3'; and GAPDH forward, 5'-CAC GCA GCA CAG TGG ACA TTC-3' and reverse, 5'-TGG ACTCCACCGCTACTCA-3'. The relative expression levels were calculated using the 2^-ΔΔCq method (19). Each sample was assayed in triplicate.

Western blotting. Protein expression was detected by western blot analysis. Cells were lysed by radioimmunoprecipitation buffer (Beyotime Institute of Biotechnology). The protein concentration in each sample was determined using a Bradford protein assay kit (Beyotime Institute of Biotechnology). The proteins were transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked with 4% skimmed milk at room temperature for 1 h, and subsequently primary antibodies were incubated with the membrane at room temperature for 2 h. The primary antibodies used were as follows: Polyclonal primary rabbit anti-iNOS antibody (cat. no. SAB4502012, Media Cybernetics, Inc., Rockville, MD, USA).
1:500 dilution; Sigma-Aldrich; Merck Millipore); polyclonal primary rabbit anti-interleukin (IL)-12 antibody (1:500 dilution, cat. no. SAB1306460; Sigma-Aldrich; Merck Millipore), polyclonal primary rabbit anti-IL-10 antibody (1:500 dilution, cat. no. SAB1410712; Sigma-Aldrich; Merck Millipore), polyclonal primary rabbit anti-arginase 1 antibody (1:500 dilution, cat. no. A6107; Sigma-Aldrich; Merck Millipore); and polyclonal primary rabbit anti-GAPDH antibody (1:2,000 dilution, cat. no. SAB2108266; Sigma-Aldrich; Merck Millipore). Membranes were subsequently incubated with secondary antibody (goat anti-rabbit IgG-peroxidase antibody, cat. no. A0545, 1:2,000 dilution; Sigma-Aldrich; Merck Millipore) at room temperature for 1 h. The blots were detected by SignalBoost™ Immunoreaction Enhancer kit (EMD Millipore) and visualized using a Kodak 440 digital imager (Kodak, Rochester, NY, USA). The analysis was performed using Kodak Molecular Imaging software, version 4.5 (Kodak). The relative protein levels were calculated using Image-Pro Plus software, version 5.0 (Media Cybernetics, Inc.) comparing the grayscale of the blots.

Immunohistochemistry. Tissue sections (6 µm) from representative paraffin blocks were de-paraffinized and rehydrated using graded ethanol and then blocked using 4% normal rabbit serum (Beyotime Institute of Biotechnology) at room temperature for 15 min. Then, primary monoclonal mouse anti-human CD68 antibody (1:200 dilution, cat. no. ab201340; Abcam, Cambridge, MA, USA) and mouse monoclonal anti-human BAMBI with 37°C for 1 h (1:200 dilution, cat. no. ab57043; Abcam) were combined with the avidin-biotin blocking solution and ABC staining kit (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), according to the manufacturer's instructions. The sections were processed in a 3,3'-diaminobenzidine/H₂O₂ solution and stained using hematoxylin (Beyotime Institute of Biotechnology). The experiment with the reagents were used according to the manufacturer's instructions. Staining was performed at room temperature for 10 min. The stained sections were observed and images captured using a Leica 400 light microscope (Leica Microsystems, Inc.).

Green-fluorescent immunostaining was performed using primary monoclonal mouse anti-human CD68 antibody (1:1,000 dilution, cat. no. ab201340; Abcam) and mouse monoclonal anti-human BAMBI (1:1,000) at 37°C for 1 h. The secondary antibody was Goat Anti-Mouse IgG H&L (FITC) (1:1,000, cat. no. ab6785; Abcam), which was incubated at room temperature for 15 min. The stained cells were observed and images captured using fluorescence microscope (DMI 3000B; Leica Microsystems, Inc.).

Statistical analysis. Data are presented as the mean ± standard deviation from three independent experiments, each performed in triplicate or quadruplicate. Statistical evaluation of data was performed using Student's t-test, one-way analysis of variance (ANOVA) or repeated measures ANOVA (SPSS 13.0 software; SPSS, Inc., Chicago, IL, USA). The Pearson correlation coefficient (R) test was performed for correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

BAMBI induces the migration of monocytes and macrophages in vitro. The present study assayed the effect of BAMBI on monocyte cells migration using Boyden chambers. RAW 264.7 monocytes were seeded in the top compartment of the chamber and enhancing concentrations of recombinant human BAMBI was added to the bottom compartment. The results demonstrated that BAMBI stimulated monocyte migration in a dose-dependent manner compared with the control cells (P=0.02; Fig. 1). To identify the on chemically-differentiated monocytes, PMA was used to stimulate the monocytes to differentiate into macrophages. BAMBI also significantly increased macrophage migration compared with the control group (P=0.03; Fig. 2), providing further evidence of the effects of BAMBI on inflammatory cells.
Positive correlation between BAMBI expression and macrophage levels. In order to validate the in vitro findings, analysis was performed on a retrospective selection of gliomas tissue specimens. CD68 is a macrophage-specific marker, and thus, was used to detect macrophages. High levels of CD68 were observed in glioma samples compared with the control specimens (Fig. 3A). Additionally, compared with normal specimens, high levels of BAMBI were detected in the gliomas tissues (Fig. 3B). The localization of BAMBI and number of macrophages exhibited similar patterns in normal and glioma tissues. qPCR analysis demonstrated that CD68 expression was significantly increased in glioma compared with normal tissue, which is similar to the result of immunohistochemistry analysis (P=0.01; Fig. 4A). Additionally, the BAMBI mRNA was significantly increased in glioma samples compared with normal tissues (P=0.02; Fig. 4B). Furthermore, correlation analysis demonstrated that BAMBI is positively correlated with CD68 in gliomas (P<0.01 and R²=0.64; Fig. 5).

BAMBI promotes the differentiation of macrophages. To determine whether BAMBI induces the proliferation of macrophages during tumorigenesis, the co-treatment of BAMBI and PMA was performed on RAW 264.7 macrophages (Fig. 6).
The result demonstrated that after 48 h treatment with BAMBI, certain cells were into dendrite-like. With BAMBI and PMA treatment, the number of dendrite-like cells was increased compared with BAMBI-only treatment. This indicated that BAMBI and PMA promote the differentiation of macrophages.

**BAMBI induces differentiation of M1 macrophages.** In order to improve the description of the BAMBI-treated macrophage phenotype, the expression of specific M1 (iNOS and IL-12) and M2 (IL-10 and arginase 1) macrophages markers was performed on BAMBI-treated RAW 264.7 cells. The results demonstrated that the protein levels of specific markers of M1 macrophages (iNOS and IL-12) were increased significantly after by with BAMBI compared with the control, indicating that BAMBI induces differentiation of monocytes to M1 type macrophages (Fig. 7). By contrast, the markers of M2 type macrophages, including IL-10 and arginase 1 were not affected by BAMBI treatment (Fig. 8). These results indicated that BAMBI induced differentiation of M1 type macrophages.

**Discussion**

Gliomas consist of two key cellular compartments; the epithelium and the surrounding stroma. Glioma cell invasion is regulated by microregional extracellular matrix...
heterogeneity (20,21). Among the inflammatory cells, macrophages have been reported to be involved in various processes associated with inflammation during tumorigenesis (22-24). However, the specific mechanisms involved and the prognostic importance of macrophages in tumorigenesis remains unclear; investigating this is important to verify additional markers. Higher expression of BAMBI in different types of cancer has been reported previously (11,13) and has been suggested that BAMBI modulates inflammation (16). To the best of our knowledge, the present study is the first to demonstrate that BAMBI stimulates the migration of monocytes and macrophages in vitro. In addition, the expression levels of BAMBI were correlated with macrophage density (indicated by CD68 expression) in human glioma specimens. It was also illustrated that BAMBI induced the expression of certain M1-specific markers, which emphasized the inflammatory-modulating effect in glioma.

BAMBI expression has been previously reported to be increased in colorectal (25) and ovarian (26) cancer. In the majority of these types of cancer, higher BAMBI expression indicated poor prognosis. A previous study suggested that BAMBI potentially regulated inflammation, particularly acting on monocytes and macrophages. The role of macrophages in cancer development is controversial. During cancer progression, polarized M2 macrophages are induced by tumor-derived and T cell-derived cytokines (9). The ratio of M2 macrophages is an indicator of poor prognosis (27). Additionally, tumor necrosis factor was demonstrated to inhibit tumor growth in the brain by promoting the recruitment of macrophages (28), which also indicated that macrophages have an anticancer effect via gene regulation.

The present study demonstrated that compared with normal tissues, macrophage density was increased in glioma samples (17,23). A previous study reported that the total number of macrophages was positively correlated with recurrence-free survival following radical treatment (29). The contradiction between these finding may be due to the role of the two different macrophages phenotypes: M1-type (classically activated) and M2-type (alternatively activated) (30). M1-type macrophages generally express iNOS, which is tumor-cytotoxic. Tumor progression stimulates a phenotypic switch to M2 macrophages that express arginase 1, and accelerate tumor growth, survival and metastasis (31). Similarly, it has been previously demonstrated that the density of iNOS-positive macrophages, which infiltrate the stroma, is decreased in highly aggressive gliomas compared with less aggressive cancer, which indicates that as malignant potential of the cancer increased, the cytotoxic activity of macrophages is reduced (32). The present study demonstrated that treatment with BAMBI increased the expression of M1-specific markers and had no effect on the expression of M2 markers, which suggests that BAMBI promoted differentiation of M1 macrophages. Thus, we hypothesize that higher expression of BAMBI may inhibit tumorigenesis.

The outcomes of the present study are valuable as they demonstrate the role of BAMBI in gliomas. BAMBI stimulated the migration of monocytes and promoted their differentiation toward the M1 inflammatory pathway. The results also indicate that macrophages and BAMBI may exert important function in glioma.

References


